All News
Filter News
Found 808,979 articles
-
New International Study Reports Extension of the Donor Lung Transplantation Window
3/12/2024
Paragonix Technologies, Inc. announces the landmark publication of the first clinical manuscript assessing the use of FDA-cleared advanced organ preservation technology to significantly extend ischemic times, a term referring to the sensitive window of time between organ recovery and transplantation.
-
OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases
3/12/2024
OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.
-
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
3/12/2024
IGC Pharma, Inc. announced that it has appointed Terry Lierman as an independent director to its board of directors.
-
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
3/12/2024
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
-
Scorpius Holdings, Inc. Announces Closing of Public Offering - March 12, 2024
3/12/2024
Scorpius Holdings, Inc., an integrated contract development and manufacturing organization, announced the closing of its previously announced public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for gross proceeds of $1,500,000, before deducting underwriting discounts and offering expenses.
-
Truveris Announces C-Suite Appointments & Leadership Promotions
3/12/2024
Truveris elevates Garrett Fienberg to Chief Operating Officer, Gregg DiPietro to Chief Commercial Officer, and Louise Shea to Chief Pharmacy Officer.
-
DOMINION DIAGNOSTICS Earns 2024 Great Place To Work Certification™
3/12/2024
Dominion Diagnostics, a leading national medical laboratory specializing in urine drug monitoring solutions is proud to announce that it has been Certified™ by Great Place To Work® in 2024.
-
Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold
3/12/2024
NANO-X IMAGING LTD and its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., announced that early findings from the ADOPT study, which uses a Nanox.AI artificial intelligence solution, HealthVCF, to review routine CT scans, have identified up to six times more patients with vertebral compression fracture than the national average at NHS hospitals in the UK, which include University of Oxford and other healthcare centers.
-
Elixirgen Scientific Achieves ISO 9001 QMS Certification
3/12/2024
Baltimore-based biotechnology leader, Elixirgen Scientific, Inc., achieves ISO 9001:2015 Quality Management System certification, strengthening commitment to quality, excellence in biotechnology and drug discovery.
-
IMUNON Announces Leadership Change
3/12/2024
IMUNON, Inc., a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Dr. Corinne Le Goff, Pharm.D. has resigned as President and Chief Executive Officer, and from the Board of Directors, to pursue another business opportunity.
-
Champions Oncology Reports Quarterly Revenue of $12.0 Million
3/12/2024
Champions Oncology, Inc., a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced its financial results for its third quarter of fiscal 2024, ended January 31, 2024.
-
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
3/12/2024
IDEAYA Biosciences, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate IDE161, the company's investigational, potential first-in-class, small molecule poly glycohydrolase, or PARG, inhibitor, in combination with KEYTRUDA® Merck's anti-PD-1 therapy, in patients with microsatellite instability-, or MSI-, high and microsatellite stable, or MSS, endometrial cancer, in a Phase 1 clinical trial.
-
DirectMed Imaging Acquires Titanium Medical Imaging
3/12/2024
DirectMed Imaging, the premier supplier of aftermarket medical imaging parts, systems, and training, announces the acquisition of Houston-based Titanium Medical Imaging, a company with vast expertise in Canon/Toshiba medical parts and systems.
-
Cencora Announces Leadership Succession Plan - March 12, 2024
3/12/2024
Cencora, Inc. announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024.
-
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
3/12/2024
Belite Bio, Inc. announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 11, 2024, is available through its website.
-
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
3/12/2024
ASLAN Pharmaceuticals Ltd. announced today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares, each ADS representing twenty-five ordinary shares, at an offering price of $1.00 per ADS in a registered direct offering.
-
Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
3/12/2024
Intelligent Bio Solutions Inc. announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 2,223,333 shares of common stock, Series H-1 warrants to purchase up to an aggregate of 2,223,333 shares of common stock and Series H-2 warrants to purchase up to an aggregate of 2,223,333 shares of common stock, at a combined purchase price of $4.55 per share of common stock and associated Series H-1 warrants and Series H-2 warrants.
-
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
3/12/2024
Everest Medicines's licensing partner Calliditas Therapeutics AB announced that the U.S. FDA has granted an orphan drug exclusivity period of seven years for Nefecon®, expiring in December 2030 based on Calliditas obtaining full approval with a new indication for this drug product in December 2023.
-
Japanese Multinational Biopharmaceutical Company Selects ValGenesis iRisk for Implementing ICH Q14 Framework
3/12/2024
ValGenesis, Inc. announced that a Japanese multinational biopharmaceutical company selected ValGenesis iRisk for implementing the ICH Q14 framework on Process Analytical Technology analytical methods across its global manufacturing sites.
-
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
3/12/2024
Genprex, Inc. announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent that covers the use of Genprex's lead drug candidate, Reqorsa® Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies through 2037.